Join to view full profile
Sepracor Inc.84 Waterford DriveSudbury, MA 01752
Phone+1 508-357-7608
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Donna Grogan, MD is an internist in Sudbury, Massachusetts. She is currently licensed to practice medicine in Massachusetts.
Education & Training
UMass Chan Medical SchoolResidency, Internal Medicine, 1983 - 1987
University of Illinois College of MedicineClass of 1983
Certifications & Licensure
MA State Medical License 1984 - 2021
Publications & Presentations
PubMed
- 30 citationsPalovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial.Robert J Pignolo, Geneviève Baujat, Edward C Hsiao, Richard Keen, Amy Wilson
Journal of Bone and Mineral Research. 2022-10-01 - 7 citationsWhole-body Computed Tomography Versus Dual Energy X‑ray Absorptiometry for Assessing Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva.Sarah E. Warner, Frederick S. Kaplan, Robert J. Pignolo, Stacy E. Smith, Edward C. Hsiao
Calcified Tissue International. 2021-07-31 - 12 citationsPatients with ACVR1 R206H mutations have an increased prevalence of cardiac conduction abnormalities on electrocardiogram in a natural history study of Fibrodysplasia ...Samuel Kou, Carmen De Cunto, Geneviève Baujat, Kelly L. Wentworth, Donna R. Grogan
Orphanet Journal of Rare Diseases. 2020-07-29
Press Mentions
Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans ProgressivaDecember 12th, 2017